Recursion (RXRX) Shares Updated Pipeline Guidance at Download Day
Recursion (RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, gave updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion’s investor and R&D day, on Monday, June 24, 2024.
“Since our last Download Day, which was approximately 18 months ago, we have seen various industries increasingly embrace AI/ML solutions. This adoption has also played out in the drug discovery space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “Over the past decade, we have created a strong leadership position by building the technological and operational capabilities of our platform in order to expand and advance our internal pipeline as well as deliver for our external partners through the integrated use of data, compute, and automation. We look forward to highlighting the various aspects of the Recursion value proposition at Download Day.”
The event features a number of prominent speakers, including Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D., Ph.D., UT Southwestern Distinguished Chair in Biomedical Science, and John Marioni, Ph.D., Senior VP and Head of Computational Sciences at Genentech.
Updated pipeline guidance – Seven Clinical Trial Readouts expected within approximately 18 months:
REC-994 Cerebral Cavernous Malformation—topline Phase 2 data readout in September 2024;
REC-2282 Neurofibromatosis Type 2—preliminary Phase 2 data readout in the fourth quarter of 2024;
REC-4881 Familial Adenomatous Polyposis—preliminary Phase 2 data readout in the first half of 2025;
REC-4881 Advanced AXIN1/APC-Mutant Cancers—preliminary Phase 2 data readout in the first half of 2025;
REC-3964 Clostridioides difficile Infection—Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025;
RBM39 Advanced HR-Proficient Cancers—IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025;
Target Epsilon (Fibrotic Diseases)—IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025.
Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline.
For additional emerging Tech and AI companies, check out the PRISM NextGen Tech and AI Index.
